|
About miRview™ squamous
- Mansukhami M, Rosenfeld N. Reply to G. Rossi et al. J Clin Oncol 27:e143-e144, 2009.
- Rossi G, Papotti M, Barbareschi M, et al: Morphology and a limited number of immunohistochemical markers may efficiently subtype non-small cell lung cancer. J Clin Oncol 27:e141-e142, 2009.
- Danit Lebanony, Hila Benjamin, Shlomit Gilad, Meital Ezagouri, Avital Dov, Karin Ashkenazi, Nir Gefen, Shai Izraeli, Gideon Rechavi, Harvey Pass, Daisuke Nonaka, Junjie Li, Yael Spector, Nitzan Rosenfeld, Ayelet Chajut, Dalia Cohen, Ranit Aharonov& Mahesh Mansukhani. A diagnostic assay based on hsa-miR-205 expression distinguishes squamous from non-squamous non small-cell lung carcinoma. J Clin Oncol, 2009 Oct 1:27(28).
- Bishop JA, Benjamin H, Cholakh H, Chajat A, Clark DP, Westra WH. Accurate classification of non–small cell lung carcinoma using a novel microRNA-based approach. Clin Cancer Res. 2010;16(2):610-619.
- Lebanony D, Benjamin H, Gilad S, et al. A diagnostic assay based on hsa-miR-205 expression distinguishes squamous from nonsquamous non-small-cell lung carcinoma. J Clin Oncol. 2009;27(12):2030-2037.
About miRview™ technology
- Arnon Afek, Kinneret Rosenblatt, Hila Tabibian-Keissar, Merav Zepeniuk, Lahav Cohen, Harel Dan, Orit Zion, Yulia Strenov, Sylvie Polak-Charcon and Marina Perelman. MicroRNA expression differentiates between primary lung tumors and metastases to the lung. Pathology Research and Practice, online publication, 28 April 2010 (doi:10.1016/j.prp2010.03.005)
- Meiri E, Spector Y, Cohen L, et al. MicroRNAs as powerful diagnostic tools for the differential diagnosis of lung tumors. Presented at: 44th American Society of Clinical Oncology Annual Meeting; May 30-June 3, 2008; Chicago, IL. Abstract 11112.
- Rosenfeld N, Aharonov R, Meiri E, et al. MicroRNAs accurately identify cancer tissue origin. Nat Biotechnol. 2008;26(4):462-469.
- Rosenwald S, Meiri E, Gilad S, et al. MicroRNA signature identifies tissue origin of primary and metastatic tumors. Presented at: 44th American Society of Clinical Oncology Annual Meeting; May 30-June 3, 2008; Chicago, IL. Abstract 11028.
- Liang Y. An expression meta-analysis of predicted microRNA targets identifies a diagnostic signature for lung cancer. BMC Med Genomics. 2008;1:61.
- Markou A, Tsaroucha EG, Kaklamanis L, Fotinou M, Georgoulias V, Lianidou ES. Prognostic value of mature microRNA-21 and microRNA-205 overexpression in non-small cell lung cancer by quantitative real-time RT-PCR. Clin Chem. 2008;54(10):1696-1704.
About pathologist interobserver variability
- Field RW, Smith BJ, Platz CE, et al. Lung cancer histologic type in the surveillance, epidemiology, and end results registry versus independent review. J Natl Cancer Inst. 2004;96(14):1105-1107.
- Stang A, Pohlabeln H, Müller KM, Jahn I, Giersiepen K, Jöckel KH. Diagnostic agreement in the histopathological evaluation of lung cancer tissue in a population-based case-control study. Lung Cancer. 2006;52(1):29-36.
About variability in the performance of immunohistochemistry markers
- Hammar SP. Immunohistology of lung and pleural neoplasms. In: Dabbs D, ed. Diagnostic Immunohistochemistry. 2nd ed. Philadelphia, PA: Churchill Livingstone; 2006:329-403.
- Camilo R, Capelozzi VL, Siqueira SA, Del Carlo Bernardi F. Expression of p63, keratin 5/6, keratin 7, and surfactant-A in non-small cell lung carcinomas. Hum Pathol. 2006;37:542-546.
- Reis-Filho JS, Simpson PT, Martins A, Preto A, Gärtner F, Schmitt FC. Distribution of p63, cytokeratins 5/6 and cytokeratin 14 in 51 normal and 400 neoplastic human tissue samples using TARP-4 multi-tumor tissue microarray. Virchows Arch. 2003;443:122-132.
- Ordóñez NG. The diagnostic utility of immunohistochemistry in distinguishing between epithelioid mesotheliomas and squamous carcinomas of the lung: a comparative study. Mod Pathol. 2006;19(3):417-428.
- Au NH, Gown AM, Cheang M, et al. P63 expression in lung carcinoma: a tissue microarray study of 408 cases. Appl Immunohistochem Mol Morphol. 2004;12(3):240-247.
- Saad RS, Liu YL, Han H, Landreneau RJ, Silverman JF. Prognostic significance of thyroid transcription factor-1 expression in both early-stage conventional adenocarcinoma and bronchioloalveolar carcinoma of the lung. Hum Pathol. 2004;35(1):3-7.
- Abutaily AS, Addis BJ, Roche WR. Immunohistochemistry in the distinction between malignant mesothelioma and pulmonary adenocarcinoma: a critical evaluation of new antibodies. J Clin Pathol. 2002;55(9):662-668.
- Tan D, Li Q, Deeb G, et al. Thyroid transcription factor-1 expression prevalence and its clinical implications in non-small cell lung cancer: a high-throughput tissue microarray and immunohistochemistry study. Hum Pathol. 2003;34(6):597-604.
|
